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ABSTRACT 
 
At present, little is known about the effect(s) of organophosphorous compounds (OPs) 
on cardiomyocytes. In this study we have investigated the effects of phenyl saligenin 
phosphate (PSP), two organophosphorothioate insecticides (diazinon and chlorpyrifos) 
and their acutely toxic metabolites (diazoxon and chlorpyrifos oxon) on mitotic and 
differentiated H9c2 cardiomyoblasts. OP-induced cytotoxicity was assessed by 
monitoring MTT reduction, LDH release and caspase-3 activity. Cytotoxicity was not 
observed with diazinon, diazoxon or chlorpyrifos oxon (48 h exposure; 200 µM). 
Chlorpyrifos-induced cytotoxicity was only evident at concentrations >100 µM. In 
marked contrast, PSP displayed pronounced cytotoxicity towards mitotic and 
differentiated H9c2 cells. PSP triggered the activation of JNK1/2, but not ERK1/2, p38 
MAPK or PKB, suggesting a role for this pro-apoptotic protein kinase in PSP-induced cell 
death. The JNK1/2 inhibitor SP 600125 attenuated PSP-induced caspase-3 and JNK1/2 
activation, confirming the role of JNK1/2 in PSP-induced cytotoxicity. Fluorescently 
labelled PSP (dansylated PSP) was used to identify novel PSP binding proteins. 
Dansylated PSP displayed cytotoxicity towards differentiated H9c2 cells. 2D-gel 
electrophoresis profiles of cells treated with dansylated PSP (25 µM) were used to 
identify proteins fluorescently labelled with dansylated PSP. Proteomic analysis identified 
tropomyosin, heat shock protein β-1 and nucleolar protein 58 as novel protein targets for 
PSP. In summary, PSP triggers cytotoxicity in differentiated H9c2 cardiomyoblasts via 
JNK1/2-mediated activation of caspase-3. Further studies are required to investigate 
whether the identified novel protein targets of PSP play a role in the cytotoxicity of this 
OP, which is usually associated with the development of OP-induced delayed neuropathy.  
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INTRODUCTION 
Organophosphorous compounds (OPs) are widely used as insecticides (e.g. diazinon and 
chlorpyrifos) due to their ability to rapidly and irreversibly inhibit acetylcholinesterase 
(AChE) activity in neuromuscular junctions and the central nervous system.1-2 However, 
over-exposure can be fatal to non-target organisms including man. Some OPs are also 
extensively used as oil additives (e.g. tri-ortho-cresyl phosphate; TOCP) due to their 
ability to retain chemical properties under extreme conditions as in the case of aviation 
hydraulic fluids.3 The increased use of OPs over recent decades has heightened concerns 
about environmental pollution and food contamination, with numerous reports of human 
toxicity. Although the clinical effects of many OPs are linked to inhibition of AChE, 
damage to skeletal and cardiac muscle has been reported in studies of acute and chronic 
exposure.4-6 Hence, on-going research into OP-induced toxicity includes unravelling the 
molecular mechanisms underlying neurotoxicity and cardiotoxicity coupled with the 
identification of novel OP protein targets. 
   Regarding neurotoxicity, studies have shown that sub-acute exposure to some OPs is 
associated with various forms of delayed toxicity in non-target species.2 The clinical 
symptoms of one of these conditions, termed OP-induced delayed neuropathy (OPIDN), 
includes partial paralysis which appears 2-3 weeks following exposure to OPs such as 
TOCP.7-9 The molecular events responsible for OPIDN include inhibition of neuropathy 
target esterase (NTE), disruption of the axonal cytoskeleton7-9 and modulation of Ca2+ 
homeostasis.10-11 At present the majority of studies have focused on the effects of OPs 
on the central nervous system. There is very little information on the effect of OPs on 
muscle function, particularly toxic effects on cardiac muscle. 
   Previous studies have documented the cardiovascular consequences of acute OP 
poisoning, which include life-threatening ventricular arrhythmias and tachycardia.12-16 
However, despite these well-known cardiac disturbances, very few studies have 
investigated the direct effects of OPs on cardiomyocyte function. A recent study explored 
the morphological changes in the rat heart following chronic treatment with a sub-lethal 
dose of the OP methamidophos, an insecticide used in many developed countries.17 
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Results indicated that repetitive doses of methamidophos induced cardiac muscle fibre 
hypertrophy, suggesting that OPs may interfere with cardiomyocyte physiology. 
Interestingly, electron microscope analysis of myocardial cells obtained from rats treated 
with diazinon revealed ultra-structural changes including vacuolisation and mitochondrial 
swelling,18 again suggesting that OPs can disrupt cardiomyocyte physiology via AChE-
independent mechanisms.  
   The aim of the present study was to investigate the effect of OPs on the viability of 
mitotic and differentiated rat embryonic cardiomyoblast-derived H9c2 cells.19 These cells 
are used as an in-vitro model system since they display similar morphological, 
electrophysiological, and biochemical properties to primary cardiomyocytes.20 The OPs 
investigated were phenyl saligenin phosphate (PSP; an active congener of the OPIDN-
inducing metabolite of TOCP), two organophosphorothioate insecticides (diazinon and 
chlorpyrifos) and their acutely toxic metabolites (diazoxon and chlorpyrifos oxon). The 
results presented show that PSP, which is classed as a weak inhibitor of AChE, displays 
marked cytotoxicity towards differentiated H9c2 cells, whereas OPs classed as strong 
AChE inhibitors exhibited little or no cytotoxicity. Furthermore, PSP-induced 
cardiotoxicity appears to involve JNK1/2- mediated activation of caspase-3. 
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MATERIALS AND METHODS 
 
Materials 
Chlorpyrifos, chlorpyrifos oxon, diazinon and diazoxon were purchased from Greyhound 
Chromatography and Allied Chemicals (Birkenhead, Merseyside, UK). Phenyl saligenin 
phosphate (PSP) and dansylated PSP were synthesised in house at Nottingham Trent 
University (Figure 1). All-trans retinoic acid was obtained from Sigma Chemical Co. 
(Poole, Dorset, UK). LY 294002, PD 98059, SB 203580, SP 600 125 and wortmannin 
were obtained from Tocris Bioscience (Bristol, UK). Dulbeco’s modified Eagle’s Medium 
(DMEM), foetal calf serum, trypsin (10X), L-glutamine (200 mM), penicillin (10,000 
U/mL)/streptomycin (10,000 µg/mL) were purchased from BioWhittaker UK Ltd. 
Antibodies were obtained from the following suppliers: monoclonal phospho-specific 
ERK1/2 (Thr202/Tyr204; M8159) from Sigma-Aldrich Co. Ltd (Poole, UK); polyclonal 
phospho-specific PKB (Ser473; 9271), polyclonal total unphosphorylated PKB (9272), 
monoclonal total unphosphorylated ERK1/2 (9107), polyclonal total unphosphorylated 
JNK (9252), monoclonal phospho-specific JNK (Thr183/Tyr185; 9251), polyclonal total 
unphosphorylated p38 MAPK (9212), monoclonal phospho-specific p38 MAPK 
(Thr180/Tyr182; 9216), and polyclonal anti- cleaved caspase-3 (9661) from New England 
Biolabs Ltd (Hitchin, UK).  All other chemicals were of analytical grade. Stock solutions of 
OPs were diluted in DMSO, which was present in all treatments including the control at a 
final concentration of 0.5% (v/v).  
 
Cell culture 
Rat embryonic cardiomyoblast-derived H9c2 cells were obtained from the European 
Collection of Animal Cell Cultures (Porton Down, UK). Undifferentiated cells were cultured in 
DMEM supplemented with 2 mM L-glutamine, 10% (v/v) foetal calf serum and penicillin 
(100 U/mL)/streptomycin (100 µg/mL). Cells were maintained in a humidified incubator 
(95% air/5% CO2 at 37°C) until 70-80% confluent and sub-cultured (1:5 split ratio) using 
trypsin (0.05% w/v)/EDTA (0.02% w/v). Differentiation of H9c2 cells was induced by 
culturing them for 7 days in DMEM supplemented with 1% (v/v) FBS and 10 nM all-trans 
 7 
 
retinoic acid.21-22 The medium was replaced every two days and differentiation into a more 
cardiomyocyte-like phenotype was confirmed by monitoring the expression of cardiac 
troponin 1 via immunocytochemistry and Western blotting.22-23  
 
Immunocytochemistry 
Activation of caspase 3 was assessed via immunocytochemical staining. H9c2 cells were 
seeded in 8-well chamber slides (BD Falcon™ CultureSlide) at a density of 15,000 
cells/well and cultured for 24 h, after which the medium was removed, replaced with 
differentiation medium and incubated for a further 7 days, changing the medium every 
two days. The medium was removed and adherent differentiated cells washed with 
phosphate buffered saline (PBS) pre-warmed to 37°C. Cells were fixed with 3.7% (w/v) 
paraformaldehyde (Sigma-Aldrich, UK) in PBS, for 15 min at room temperature without 
agitation and washed gently three times for 5 min with PBS. After fixation, 
permeabilisation was performed by incubating cells for 15 min at room temperature with 
0.1% (v/v) Triton X-100 in PBS followed by washing three times for 5 min with PBS. 
Cells were incubated for 1 h at room temperature with 3% (w/v) bovine serum albumin 
(BSA) in PBS (BSA/PBS) to prevent non-specific antibody binding. They were incubated 
overnight at 4oC in a humidified chamber with anti-cleaved caspase-3 antibody (1:500) 
in BSA/PBS. Unbound primary antibody was then removed and the wells washed three 
times for 5 min with PBS. Cells were incubated for 2 h at 37oC in a humidified chamber 
with fluorescein isothiocyanate (FITC)-conjugated anti-mouse immunoglobulin G 
(Abcam, Cambridge, UK), diluted 1:1000 in 3% (w/v) BSA in PBS. The chamber slide 
was subsequently washed three times for 5 min with PBS, air dried and mounted with 
Vectashield medium (Vector Laboratories Ltd, Peterborough, UK) containing DAPI 
counterstain for nuclei visualisation. Finally slides were sealed using clear, colourless nail 
varnish and stained cells visualised using an Olympus DP71 epifluorescence microscope 
system equipped with an argon/krypton laser (FITC: Ex493/Em528; DAPI: Ex360/Em460).  
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MTT assay 
Undifferentiated H9c2 cells were plated in 24-well flat-bottomed plates at a final density of 
15,000 cells/well and cultured for 24 h in fully supplemented DMEM. Cells were 
subsequently induced to differentiate for 7 days, as described above, prior to 
organophosphate treatment. Following organophosphate exposure cell viability was 
determined by measuring the metabolic reduction of MTT (3-(4-5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide) to a purple coloured formazan product. Briefly, cells were 
incubated for 1 h in 0.5 mg/mL MTT (in the continued presence of OP) after which the 
medium was removed and replaced with 200 µL DMSO. The magnitude of the reduction 
reaction was determined by monitoring the absorbance of the solubilised formazan product 
at 570 nm. 
 
Lactate dehydrogenase assay 
H9c2 cells were plated in 96-well flat bottomed plates at a final density of 5,000 
cells/well and cultured for 24 h in fully supplemented DMEM. Cells were subsequently 
induced to differentiate for 7 days prior OP treatment. Following OP exposure the activity 
of lactate dehydrogenase (LDH) released into the culture medium was detected 
colourimetrically using the CytoTox 96® Non-Radioactive Cytotoxicity assay (Promega, 
Southampton, UK). Assays were performed according to the manufacturer’s instructions 
and changes in absorbance monitored at 490 nm. 
 
Acetylcholinesterase assay 
H9c2 cells induced to differentiate for 7 days in 175 cm2 cell culture flasks were detached 
by trypsinisation and collected by centrifugation in ice cold PBS. They were resuspended 
in 0.1 M phosphate buffer containing 0.2 % (v/v) Triton X-100 and assayed for 
acetylcholinesterase activity,24 adapted for microtitre plate format.25 Absorbance change 
at 405 nm was linear over a 10 min period. Data were expressed as mean specific 
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activity (absorbance change/min/mg protein) from at least three independent 
experiments. 
 
Western blot analysis of protein kinase phosphorylation and caspase 3 
activation 
Analysis of protein kinase phosphorylation was performed using H9c2 cells differentiated 
for 7 days in 25 cm2 tissue culture flasks. Following experimentation, cell supernatants 
were removed and the cells washed twice with 37°C PBS to remove serum proteins. A 
volume of  300 L of hot (100°C) sodium dodecyl sulphate buffer (0.5% w/v SDS in Tris 
buffered saline) was added and the resulting cell lysate boiled for 5 min prior to storage 
at -20°C. Protein concentration was determined using the Bio-Rad DC™ Protein Assay kit 
(Bio-Rad laboratories, Hertfordshire, UK) with BSA as the standard.  
   Protein samples (15 µg) were separated by sodium dodecyl sulphate/polyacrylamide 
gel electrophoresis (SDS/PAGE; 10 % (w/v) polyacrylamide gel) using a Bio-Rad Mini-
Protean III system. Proteins were transferred to nitrocellulose membranes using a Bio-
Rad Trans-Blot system (1 h at 100 V in 25 mM Tris, 192 mM glycine and 20% MeOH). 
Following transfer, the membranes were washed with Tris-buffered saline (TBS) and 
blocked for 1 h at room temperature in blocking buffer (5% (w/v) skimmed milk powder, 
0.1% (v/v) Tween-20 in TBS). Blots were incubated overnight at 4oC in blocking buffer 
with the following primary antibodies (1:1000 dilution unless otherwise indicated): 
phospho-specific ERK1/2, phospho-specific PKB (1:500), phospho-specific p38 MAPK, 
and phospho-specific JNK or cleaved active caspase 3 (1:500). The primary antibody was 
removed and the blot extensively washed three times for 5 min in TBS/Tween 20. Blots 
were then incubated for 1 h at room temperature with the appropriate secondary 
antibody (1:1000) coupled to horseradish peroxidase (DAKO Ltd, Cambridge, UK) in 
blocking buffer.  
  Following removal of the secondary antibody, blots were extensively washed as above 
developed using the Ultra Chemiluminescence Detection System (Cheshire Sciences Ltd, 
Chester, UK) and quantified by densitometry using Advanced Image Data Analysis 
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Software (Fuji; version 3.52). The uniform transfer of proteins to the nitrocellulose 
membrane was routinely monitored by transiently staining the membranes with Ponceau 
S stain (Sigma-Aldrich Co. Ltd) prior to application of the primary antibody. In addition, 
replicate samples from each experiment were analysed on separate blots using total 
ERK1/2, PKB, p38 MAPK and JNK (all 1:1000 dilution) primary antibodies in order to 
confirm the uniformity of protein loading. 
 
 
2D gel electrophoresis  
Two-dimensional gel electrophoresis was performed using differentiated H9c2 cells (7 
days) cultured in 75 cm2 tissue culture flasks. Following experimentation, culture 
supernatants were removed and cells washed twice with warm PBS (37°C) to remove 
serum proteins and lysed in 300 µL urea lysis buffer (8 M urea, 50 mM DTT, 4 % w/v 
CHAPS, 0.2 % v/v Bio-Lyte® 3/10 ampholyte; Bio-Rad, UK).   
  Samples (300 µg protein) were applied onto ReadyStrip™ IPG strips (pH 3-10; Bio-Rad, 
UK) and passively rehydrated for 1 h, then actively rehydrated for 16 h at 50 V followed 
by IEF (250 V for 20 min linear, 400 V for 2 h linear, 4000 V for 10,000 V/h rapid; slope 
down to 500 V for 25 h) using a PROTEAN IEF cell (Bio-Rad, UK).  Strips were 
transferred to equilibration buffer (6 M urea, 2% (w/v) SDS, 50% (v/v) glycerol, 2% 
(w/v) DTT, 1.5 M Tris/HCl pH 8.8,) for 10 min followed by a further 10 min in 2.5% 
(w/v) iodoacetamide in equilibration buffer. Following equilibration, IPG strips were 
subjected to SDS-PAGE in a 15% (w/v) polyacrylamide gel using a Bio-Rad Mini-Protean 
III system. After electrophoresis, gels were visualised and dansylated-PSP labelled 
proteins visualised under UV light (Syngene G-box) and then stained for 16 h using 
ProtoBlue™ safe colloidal Coomassie G-250 stain (Bio-Rad, UK) and photographed using 
a Syngene G-box with GeneSnap software (version 7.12.06). Images were analysed 
using Progenesis SameSpots (V 3.1.3030.23662) software (Nonlinear Dynamics, UK).   
  
 
 11 
 
Mass Spectrometry analysis 
Selected spots were excised from the gel and dehydrated in acetonitrile for 5 min at 
37°C under gentle agitation, rehydrated in 25 mM NH4HCO3 for 10 min, and sequentially 
dehydrated, rehydrated and dehydrated. The gel pieces were incubated with mass 
spectrometry grade trypsin (Trypsin Gold; Promega; 0.55 µg per spot in 25 µl of 66.4 
mM ammonium bicarbonate) for 16 h at 37°C after which the reaction was terminated 
by adding 1% v/v trifluoroacetic acid (TFA). After tryptic digestion, peptides were de-
salted and concentrated prior to MALDI-TOF mass spectrometry using C18 ZipTips (200 Å 
pore size; Millipore, UK). Finally, 1.5 µL of the peptide digest was spotted onto a MTP 
384 Ground Steel MALDI target plate (Bruker; Germany) together with 1.5 µL of 5 
mg/mL α-cyano-4-hydroxycinnamic acid (CHCA) matrix mixture (Bruker Daltonics, UK) 
in 50 % (v/v) acetonitrile, 0.1% (v/v) TFA. Peptides were analysed using a Bruker 
UltrafleXtreme™ MALDI-TOFTOF mass spectrometer (reflectron positive mode, ion 
suppression m/z 650, mass range m/z 0-4000). Proteins were identified using Bruker-
Daltonics Biotools (v 3.2, build 2.3) software, searched against SwissProt database, rat 
species, using Mascot (version 2.3 server, Matrix Science, UK), PMF 100 ppm tolerance 
and reported according to percentage sequence coverage (SC%). MS/MS search 
parameters; MS tolerance 100 ppm, MS/MS tolerance 0.8 Da, three missed cleavages. 
All identified proteins exhibited Mascot scores which were considered statistically 
significant (p< 0.05). 
 
Binding of dansylated PSP to purified tropomyosin 
To validate the identification of one of the proteins labelled by dansylated PSP, purified 
human heart tropomyosin (10 µg; Lee Biosolutions, USA) was incubated for 1 h with 25 
µM dansylated PSP or un-labelled PSP. The purified tropomyosin was subjected to SDS-
PAGE on a 10% (w/v) polyacrylamide gel and fluorescence visualised under UV light.  
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Data analysis 
Unless otherwise specified, statistical significance was determined by ANOVA with a post 
hoc Tukey test (p<0.05 was considered statistically significant). Organophosphate IC50 
values (concentrations of drug producing 50% of the maximal inhibition) derived from MTT 
assays and EC50 values (concentrations of drug producing 50% of the maximal stimulation) 
derived from LDH assays were obtained by computer assisted curve fitting using Prism 
software (GraphPAD version 6, California, USA). All data are presented as means  S.E.M. 
The n in the text refers to the number of separate experiments. The number of replicates 
within each experiment is indicated, were appropriate, in the Figure legend. 
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RESULTS 
Effects of organophosphates on the viability of mitotic H9c2 cells 
  H9c2 cells are derived from embryonic rat heart tissue19 and have been used widely as 
an in vitro model, since they display similar morphological, electrophysiological and 
biochemical properties to primary cardiac myocytes.20 Initial experiments investigated 
the effects of OPs on the viability of mitotic H9c2 cells, which display properties of 
skeletal muscle. The effects of OP treatment on cell viability were assessed by 
monitoring MTT reduction (a measure of cellular dehydrogenase activity) and 
measurement of LDH activity released into the culture medium. At concentrations of up 
to 200 µM both diazinon and its acutely toxic metabolite diazoxon had no significant 
effect on MTT reduction or LDH release following 48 h exposure (data not shown). 
Chlorpyrifos at 200 µM and 100 µM inhibited MTT reduction following 24 h and 48 h 
exposure (Figure 2) but had no effect on LDH release at these time points (data not 
shown). In contrast, chlorpyrifos oxon at concentrations up to 200 µM had no significant 
effect on MTT reduction or LDH release after 48 h exposure (data not shown).  
   Phenyl saligenin phosphate (PSP; an active congener of the OPIDN-inducing metabolite 
of TOCP) significantly inhibited the reduction of MTT and triggered the release of LDH 
following 24 h and 48 h treatment (for clarity data not shown). Subsequent experiments 
assessed the effects of PSP on MTT reduction and LDH release at earlier time points e.g. 
1, 2, 4, and 8 h (Figure 3). The data from these experiments revealed that PSP-induced 
inhibition of MTT reduction was first evident at 4 h (IC50 = 8.5  5.5 µM), with 
comparable results obtained at 8 h exposure (IC50 = 7.1  4.7 µM). Similarly, significant 
LDH release was first evident at 4 h (EC50 = 13  1.1 µM) and at 8 h (EC50 = 13  1.5 
µM), with levels of LDH release comparable to those observed following 24 h treatment 
All IC50 and EC50 plots are shown in Supplementary data Figure 1. Overall, these data 
indicate that PSP displays marked cytotoxicity towards mitotic H9c2 cells. 
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Effects of organophosphates on the viability of differentiated H9c2 cells 
  Mitotic H9c2 cells can be differentiated into a more cardiomyocyte-like phenotype by 
culturing the cells for 7 days in DMEM supplemented with 1% (v/v) FBS and 10 nM all-trans 
retinoic acid.21-22 Therefore, we investigated the effects of OPs on the viability of 
differentiated H9c2 cells. H9c2 differentiation was confirmed by monitoring the expression 
of cardiac troponin 1 by immunocytochemistry and Western blotting (data not shown) as 
originally described by Comelli et al.22 and confirmed in-house.23 At concentrations up to 
200 µM, both diazinon and diazoxon had no significant effect on MTT reduction or LDH 
release following 48 h exposure (data not shown).  Chlorpyrifos at 200 µM and 100 µM 
inhibited MTT reduction following 24 and 48 h exposure and at 200 µM triggered a small 
but significant release in LDH at these time points (Figure 4). In contrast, chlorpyrifos 
oxon at concentrations up to 200 µM had no significant effect on MTT reduction or LDH 
release after 48 h exposure (data not shown).  
   In differentiated cells, PSP significantly inhibited the reduction of MTT and triggered 
the release of LDH following 24 h and 48 h treatment (for clarity, data not shown). 
Subsequent experiments assessed the effects of PSP on MTT reduction and LDH release 
at earlier time points e.g. 1, 2, 4, and 8 h (Figure 5). The data from these experiments 
revealed that PSP-induced inhibition of MTT reduction was first evident at 2 h (IC50 = 6.5 
 1.2 µM), with further inhibition observed following 4 h (IC50 = 12.8  4.9 µM) and 8h 
(IC50 = 25  9.3 µM) exposure. In contrast, LDH release was first evident at 4 h (EC50 = 
15.8  6.1 µM) and increased at 8 h (EC50 = 15.1  4.3 µM), when levels of LDH release 
were comparable to those observed following 24 h treatment. All IC50 and EC50 plots are 
shown in Supplementary data Figure 2. Overall, these data indicate that PSP induces 
cytotoxicity in differentiated H9c2 cells. However, it should be noted that 100 % cell 
death was not achieved at any OP concentration or exposure time point. This could be 
due to a gradual loss of OP over time, for example due to serum protein binding or 
inactivation by enzymic and/or non-enzymic pathways. As the OPs used are hydrophobic 
they may also come out of solution at higher concentrations and longer exposure times, 
thus negating their potential to kill all of the cells. 
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   Whilst MTT reduction and LDH release and are widely used markers of cell viability, 
they do not discriminate between apoptotic and necrotic forms of cell death. To assess 
whether PSP-induced cell death involved apoptosis, we measured caspase-3 activation 
following PSP treatment. Caspase-3 activation was initially monitored by Western 
blotting using an antibody that recognises the large fragments (17/19 kDa) of activated 
caspase-3. As evident in Figure 6A, treatment of differentiated H9c2 cells with 25 M PSP 
for 4 h triggered a significant increase in caspase-3 activation. Similar results were 
obtained when PSP-induced caspase-3 activation was monitored via 
immunocytochemistry (Figure 6B).  
  In order to establish the relationship between the above cytotoxic effects and the level 
of AChE activity, cholinesterase assays were performed in the presence and absence of 
PSP. As can be seen in Figure 7, PSP was a very weak inhibitor of AChE activity in H9c2 
cells, with exposure to 25 µM causing only approximately 30% inhibition compared to 
control levels of activity. Additional experiments (data not shown) indicated much 
stronger inhibition of AChE by chlorpyrifos oxon. 
 
Effects of PSP on protein kinase phosphorylation 
PSP-induced cell death in mitotic and differentiated H9c2 cells may involve the 
modulation of pro-survival and/or pro-apoptotic signalling pathways. It is generally 
accepted that extracellular signal-regulated kinases 1 and 2 (ERK1/2) and protein kinase 
B (PKB; also known as Akt) activation promotes cell survival by activating anti-apoptotic 
signalling pathways, whereas the activation of c-Jun N-terminal kinases (JNK) and p38 
mitogen-activated protein kinases (p38 MAPK) are associated with apoptotic cell 
death.26-27 PSP-induced modulation of protein kinase activity was assessed by Western 
blotting using phospho-specific antibodies that recognise phosphorylated motifs within 
activated ERK1/2 (pTEpY), p38 MAPK (pTGpY), JNK (pTPpY) and PKB (S473). Treatment of 
differentiated H9c2 cells for 1h, 2h, 4h and 8h with PSP (25 µM) had no significant effect on 
the levels of phosphorylated ERK1/2, p38 MAPK or PKB (data not shown). In marked 
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contrast, PSP (25 µM) induced a time-dependent increase in JNK1/2 activation in 
differentiated H9c2 cells (Figure 8).   
 
 
Role of protein kinases in PSP-induced cell death 
To investigate the further the role of JNK1/2 in PSP-induced cell death, differentiated 
H9c2 cells were pre-treated for 30 min with the JNK1/2 inhibitor SP 600125 (10 µM),28 
prior to OP exposure. As shown in Figure 9, SP 600125 had no significant effect on 25 
µM PSP-induced inhibition of MTT reduction or LDH release following 4 h or 8 h OP 
exposure. Western blot analysis was subsequently used to establish whether SP 600125 
(10 µM) attenuates PSP-induced JNK1/2 activation in H9c2 cells. As depicted in Figure 
10, SP 600125 significantly inhibited PSP (25 µM)-induced JNK1/2 activation following 1h 
and 2 h OP exposure. However, SP 600125 did not block PSP-induced JNK1/2 activation 
after 4 h of exposure, which presumably accounts for the lack of effect observed with SP 
600125 when monitoring PSP-induced inhibition of MTT reduction and release of LDH at 
4 h and 8 h (Figure 9). Since PSP-induced caspase-3 activation was evident at 1 h and 2 
h OP exposure, we determined the effect of SP 600125 on PSP-induced caspase-3 
activation at these earlier time points via immunocytochemistry. As shown in Figure 11, 
SP 600125 (10 µM) attenuated PSP-induced caspase-3 activation confirming the 
involvement of JNK1/2 in PSP-mediated cell death in H9c2 cells. For comparison the 
kinase inhibitors PD 98059 (50 µM; MEK1/2 inhibitor), LY 294002 (30 µM; PI-3K 
inhibitor), wortmannin (100 nM; PI-3K inhibitor), and SB 203580 (30 µM; p38 MAPK 
inhibitor) had no significant effect on PSP-induced caspase-3 activation (data not 
shown). 
 
Identification of PSP binding proteins 
The results presented thus far indicate that PSP triggers cell death in H9c2 cells via 
JNK1/2 activation. In order to explore further the mechanism(s) of PSP-induced 
cytotoxicity we carried out studies using fluorescently labelled PSP (dansylated PSP) in 
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order to identify novel PSP binding proteins. Initial experiments confirmed that 
dansylated PSP caused similar levels of cytotoxicity as PSP in differentiated H9c2 cells 
(Figure 12). Identification of dansylated PSP labelled proteins was achieved by 2D-gel 
electrophoresis of cell lysates obtained from cells treated with dansylated PSP (1 h, 25 
µM; see Figure 13) followed by MALDI-TOF analysis of the peptides produced by trypsin 
digestion. Mass spectrometry analysis identified tropomyosin, heat shock protein 27 and 
nucleolar protein 58 as novel protein targets for PSP (Table 1). Tropomyosin was chosen 
for validation by incubation of purified human tropomyosin with dansylated PSP, followed 
by visualisation using SDS-PAGE. The data shown in Figure 14, confirmed that 
tropomyosin was labelled by dansylated PSP in H9c2 cells. 
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DISCUSSION 
  At present there is very little information on the direct effect of OPs on muscle function 
and, in particular, their toxic effects on cardiomyocytes. In this study we investigated the 
effect of OPs on mitotic and differentiated H9c2 cardiomyoblasts. Initial experiments 
examined chlorpyrifos and diazinon and their in vivo metabolites diazoxon and 
chlorpyrifos oxon. Cytotoxicity was not observed with diazinon, diazoxon or chlorpyrifos 
oxon (48 h exposure; 200 µM), whereas chlorpyrifos-induced cytotoxicity was only 
evident at concentrations >100 µM. These results are in stark contrast to the 
cardiovascular consequences of acute OP poisoning, which reflects over-activity of 
sympathetic and parasympathetic pathways due to enhanced levels of acetylcholine.12-16 
In summary, OPs that mediate acute in vivo toxicity, primarily via AChE inhibition, 
display little cytotoxicity towards H9c2 cardiomyoblasts. In marked contrast, PSP 
displayed pronounced cytotoxicity towards mitotic and differentiated H9c2 cells. PSP is 
an analogue of saligenin cyclic-o-tolyl phosphate (SCOTP), the in vivo metabolite of 
TOCP, and is classed as a weak inhibitor of AChE.29 Hence the cytotoxic effects of PSP 
observed in this study are presumably mediated via non-cholinergic mechanisms. The 
data from AChE activity assays confirm the weak effect of PSP on cholinesterase activity 
under the same experimental conditions, indicating that acute effects on AChE were not 
involved. However, it is important to note PSP is a potent inhibitor of 
butyrylcholinesterase, the activity of which is higher than acetylcholinesterase in rat 
heart. 30-31 Hence, in future work it would be of interest to monitor the effect of PSP on 
butyrylcholinesterase activity in H9c2 cells.  
  PSP is used in neuronal cell models investigating the molecular targets responsible for 
OP-induced delayed neuropathy (OPIDN), a condition associated with OPs such as 
TOCP.7-9 TOCP is an isomer of tricresyl phosphate (TCP), an OP with a wide range of 
applications due to its flame retardant and lubricant properties.32 For example, it is used 
in the aviation industry as a fuel and hydraulic fluid additive but also as a plasticiser, 
waterproofing agent and solvent. Since isomers of TCP have been detected in air cabins 
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and cockpits on commercial and military aircraft, it has been suggested that OP 
poisoning may be involved in the phenomenon of air cabin sickness.33 At present the 
cellular effect(s) of neuropathic OPs, such as PSP, on cardiomyocytes are largely 
unknown.  
Mechanisms of PSP-induced cytotoxicity 
In this study we initially assessed PSP-induced cytotoxicity by monitoring MTT reduction 
and LDH release. It is notable that PSP-induced toxicity was evident at 2 h when 
monitoring MTT reduction, whereas PSP toxicity assessed by LDH release was first 
detectable at 4 h.  The difference in sensitivity between MTT and LDH assays is in 
agreement with previous studies, which have reported the MTT assay as being more 
sensitive in detecting cytotoxic events.34 Treatment with PSP (25 µM) also triggered the 
rapid activation of caspase 3, suggesting that PSP-induced cytotoxicity involves apoptotic 
cell death. These cytotoxic effects are consistent with previous studies showing that PSP 
triggers a decrease in MTT reduction in mouse N2a neuroblastoma and human hepatic 
HepG2 cells (IC50 values of approximately 10-15 µM),35 and activation of caspase 3 in 
SH-SY5Y human neuroblastoma cells (10 and 100 µM).36 The IC50 values for PSP-induced 
toxicity obtained in this study (circa 10-20 µM) are comparable to those reported in N2a 
and HepG2 cells.35   
   In order to understand more clearly the mechanism(s) of PSP-induced cytotoxicity, the 
effect of PSP exposure on protein kinase cascades associated with cell survival (ERK1/2 and 
PKB) and cell death (p38 MAPK and JNK) was investigated. In view of their respective roles 
in cell death and cell survival, it would be predicted that PSP-induced cytotoxicity may 
involve attenuation of ERK1/2 and PKB signalling and/or activation of p38 MAPK and JNK. 
PSP did not significantly modulate ERK1/2, p38 MAPK or PKB phosphorylation status in 
differentiated H9c2 cells. However, PSP (25 µM) triggered a robust and time-dependent 
activation of JNK1/2. These data are in agreement with previous studies that have reported 
the modulation of protein kinase signalling by sub-lethal concentrations of PSP. For 
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example, PSP triggered activation of ERK1/2 in mouse N2a neuroblastoma cells (2.5 µM; 4 
h)37 and activation of PKB in human SH-SY5Y neuroblastoma cells (0.1 µM).38 It is notable 
that the effect of PSP on PKB activation in SH-SY5Y cells was a consequence of OP-induced 
activation of the low affinity neurotrophin p75 receptor.38 Further studies are required in 
order to elucidate the molecular mechanism(s) of PSP-induced JNK1/2 activation in 
differentiated H9c2 cells. 
   To verify the role of JNK1/2, we determined the effect of the JNK1/2 inhibitor SP 
600125 on PSP-induced inhibition of MTT reduction and release of LDH. Pre-treatment 
with SP 600125 had no significant effect on 25 µM PSP-induced inhibition of MTT 
reduction or LDH release following 4 h or 8 h OP exposure. However, subsequent 
experiments revealed that, whilst SP 600125 attenuated PSP-induced JNK1/2 activation 
following 1 h and 2 h PSP exposure, it was ineffective at blocking PSP-induced JNK1/2 
activation at 4 h. These observations presumably account for the lack of effect of SP 
600125 when assessing cell viability at 4 h and 8 h time points, using MTT and LDH 
assays. The reversible inhibition of PSP-induced JNK1/2 activation by SP 600125 may 
reflect removal of the inhibitor from the cell (although the inhibitor was present 
throughout the experiment) and/or metabolism to an inactive metabolite. However, SP 
600125 did block caspase 3 activation at 1 h confirming the involvement of JNK1/2 in 
PSP-induced apoptosis. It is interesting to note that although SP 600125 blocked 
caspase 3 activation at 4 h, it did not block PSP-induced JNK1/2 activation at 4 h. This is 
presumably a consequence of caspase 3 activation being downstream of JNK1/2 and 
hence inhibition of JNK1/2 at early time points ( 2 h) prevents subsequent caspase 3 
activation.     
In terms of the clinical relevance of our data, similar levels of neurodegenerative 
metabolite saligenin cyclic -o-tolyl phosphate (of which PSP in a structural analogue) are 
more likely to be achieved in heart tissue after deliberate or accidental exposure to 
significant amounts of tri-ortho-cresyl phosphate, than via normal levels of occupational 
exposure. However, given that the activation of caspase-3 occurs within the first hour of 
 21 
 
exposure to 25 µM PSP, it is possible that such levels could  be achieved only transiently 
in vivo. In this respect it is interesting to note that levels of more than 100 µM TOCP (39 
µg/g) were observed in heart tissue from rats given repeated oral doses (50 mg/kg) of 
this compound, suggesting that relatively high levels of metabolite are achievable.39 It 
may also be that longer exposure to PSP at lower concentrations can also induce caspase 
activation. In this respect, preliminary data (not shown) indicate that LDH release is 
significantly increased by exposure to 6 µM PSP for 24-48 h.  
Identification of PSP binding proteins 
  It is becoming increasing apparent that OPs interact with and/or modulate a number of 
molecular targets besides AChE.  These include cytoskeletal proteins, proteolytic 
enzymes, mitochondrial enzymes, and signalling molecules.2,38 Furthermore, a prominent 
target for OPs that induce OPIDN, is neuropathy target esterase (NTE), a member of the 
patatin-like phospholipase (PNPLA) family whose functions include regulation of lipid 
metabolism and cell signalling.40-41 Although NTE (PNPLA6) has been detected in non-
neuronal tissues including human heart,42 it is not known if mitotic or differentiated H9c2 
cells express NTE. Although beyond the scope of the present study, it would be of 
interest to investigate NTE expression and the effect of PSP on NTE activity in H9c2 cells.  
  In this study, we used fluorescently labelled PSP (dansylated PSP) in order to identify 
novel PSP binding proteins in H9c2 cardiomyocytes. Mass spectrometry analysis 
identified tropomyosin, heat shock protein β-1 and nucleolar protein 58 as novel protein 
targets for PSP. Heat shock protein β-1 (also known as HSP-27) is a member of small 
heat shock protein family and is involved in the regulation of apoptosis, protection of 
cells against oxidative stress and modulation of the cytoskeleton.43-44 Hence it is 
plausible that PSP binding modulates the functioning of heat shock protein β-1 leading to 
induction of apoptosis. In skeletal and cardiac muscle tropomyosin regulates the 
interaction between actin and myosin, whereas in non-muscle cells it plays a role in 
regulating the actin cytoskeleton.45 Given the emerging role of the actin cytoskeleton as 
a regulator of apoptosis,46 it is conceivable that PSP binding to tropomyosin alters its 
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interaction with other actin binding proteins (e.g. cofilin) that are linked to cytoskeleton 
mediated modulation of apoptotic signalling.46 Finally, PSP also bound to nucleolar 
protein 58 which is required for 60S ribosomal subunit biogenesis.47 PSP binding to this 
protein might impair the translation of proteins essential for cell survival. It is important 
to note that the observed molecular weight (kDa) and isoelectric point (pI) values for 
nucleolar protein 58 are lower than the expected values suggesting the identification of a 
proteolytic degradation product. Further work is therefore required in order to confirm 
the identity of nucleolar protein 58  as a PSP-binding protein. Overall, it remains to be 
established if there is a definitive link between any of these novel protein targets and 
PSP-induced cytotoxicity. 
 
  In summary, this study has investigated for the first time the effect of OPs on 
cardiomyocytes using differentiated H9c2 cells, a cell-based model system that displays a 
robust cardiomyocyte-like phenotype. The in vivo metabolites of OPs classified as potent 
AChE inhibitors (diazoxon and chlorpyrifos oxon) displayed no cytotoxicity towards 
mitotic or differentiated H9c2 cells. In contrast, PSP, a weak AChE inhibitor, triggered 
cytotoxicity in differentiated H9c2 cardiomyoblasts via a pathway involving JNK1/2-
mediated activation of caspase-3.  Furthermore, proteomic analysis using fluorescently 
labelled PSP identified tropomyosin, heat shock protein β-1 and nucleolar protein 58 as 
novel protein targets for PSP. Finally, whilst this study has focused on the effects and 
mechanisms of cytotoxic concentrations of PSP, on-going studies are exploring the 
effect(s) of sub-lethal concentrations of PSP on the differentiation of H9c2 cells and 
potential modulation of G-protein coupled receptor signalling pathways associated with 
cardiomyocytes.  
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AChE, acetylcholinesterase; BAS, bovine serum albumin; ERK1/2; extracellular signal-
regulated kinase 1/2; JNK1/2, c-Jun N-terminal kinase 1/2; LDH, lactate dehydrogenase; 
MTT, 3-(4-5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide;  NTE, neuropathy 
target esterase; OP, organophosphorous compounds; OPIDN, OP-induced delayed 
neuropathy; PI-3K; phosphatidyl inositol 3-kinase; PKB, protein kinase B; p38 MAPK, 
p38 mitogen-activated protein kinase; PSP, phenyl saligenin phosphate; TBS, Tris-
buffered saline; TOCP, tri-ortho-cresyl phosphate;  
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FIGURE LEGENDS 
 
Figure 1. Chemical structures of A) phenyl saligenin phosphate (PSP) and B) dansylated 
PSP. 
 
Figure 2. Effect of chlorpyrifos on the viability of mitotic H9c2 cells monitored by MTT 
reduction.  Mitotic H9c2 cells were exposed to the indicated concentrations of 
chlorpyrifos for A) 24 h and B) 48 h. Following chlorpyrifos exposure cell viability was 
assessed by measuring the metabolic reduction of MTT by cellular dehydrogenases. Data 
are expressed as the percentage of control cells (=100%) and represent the mean  SEM 
of four independent experiments each performed in quadruplicate. ****p0.0001 versus 
control response. 
 
Figure 3. Effect of phenyl saligenin phosphate (PSP) on the viability of mitotic H9c2 cells 
monitored by MTT reduction and LDH release.  Mitotic H9c2 cells were exposed to the 
indicated concentrations of PSP for 4 h (panels A and B) 8 h (panels C and D). Following 
PSP exposure cell viability was assessed by measuring the metabolic reduction of MTT by 
cellular dehydrogenases (A and C) and release of LDH (B and D). Data are expressed as 
the percentage of control cells (=100%) and represent the mean  SEM of three 
independent experiments each performed in quadruplicate (MTT) or sextuplicate (LDH). 
*p0.05, ** p<0.01, ***p<0.001 and ****p<0.0001 versus control response. 
 
Figure 4. Effect of chlorpyrifos on the viability of differentiated H9c2 cells monitored by 
MTT reduction and LDH release.  Differentiated H9c2 cells (7 day) were exposed to the 
indicated concentrations of chlorpyrifos for 24 h (panels A and B) 48 h (panels C and D). 
Following chlorpyrifos exposure cell viability was assessed by measuring the metabolic 
reduction of MTT by cellular dehydrogenases (A and C) and release of LDH (B and D). 
Data are expressed as the percentage of control cells (=100%) and represent the mean 
 SEM of three independent experiments each performed in quadruplicate (MTT) or 
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sextuplicate (LDH). *p0.05, ** p<0.01, ***p<0.001 and ****p<0.0001 versus control 
response. 
 
Figure 5. Effect of phenyl saligenin phosphate (PSP) on the viability of differentiated 
H9c2 cells monitored by MTT reduction and LDH release.  Differentiated H9c2 cells (7 
day) were exposed to the indicated concentrations of PSP for 2 h (panel A), 4 h (panels 
B and D) 8 h (panels C and E). Following PSP exposure cell viability was assessed by 
measuring the metabolic reduction of MTT by cellular dehydrogenases (A, B, C) and 
release of LDH (D, E). Data are expressed as the percentage of control cells (=100%) 
and represent the mean  SEM of at least three independent experiments each 
performed in quadruplicate (MTT) or sextuplicate (LDH). *p0.05, ** p<0.01, 
***p<0.001 and ****p<0.0001 versus control response. 
 
 
Figure 6. PSP-induced caspase-3 activation in differentiated H9c2 cells. Differentiated 
H9c2 cells (7 day) were incubated without (-) or with (+) 25 µM PSP for the indicated 
time periods. Following PSP exposure caspase-3 activation was assessed via A) Western 
blotting using anti-active caspase 3 antibody or B) via immunocytochemistry using anti- 
active caspase 3 antibody (green) and DAPI counterstain for nuclei visualisation (blue). 
Images presented are from one experiment and representative of three. In (A) data are 
expressed as the percentage of reactivity control cell lysates and represent the mean  
SEM of three independent experiments. *p0.05 versus time matched control cells. 
 
Figure 7.  Effects of PSP on acetylcholinesterase activity. Cells were induced to 
differentiate for 7 days and then exposed to PSP (8h, 25 µM). Shown are the mean 
specific activities ± SEM from three independent experiments. Asterisk indicates a 
significant difference from the non PSP treated control (Student’s T test; p<0.05). 
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Figure 8. PSP-induced JNK1/2 activation in differentiated H9c2 cells. Differentiated H9c2 
cells (7 days) were exposed to 25 µM PSP for the indicated time periods. Following PSP 
exposure JNK1/2 activation was assessed via Western blotting using a phospho-specific 
JNK1/2 antibody. Samples were subsequently analysed on separate blots using an 
antibody that recognises total JNK1/2. Quantified data are expressed as the ratio of 
phosphorylated JNK1/2 to total JNK1/2 and represent the mean  SEM of four 
independent experiments. ****p0.0001 versus control cells.   
 
Figure 9. Effect of the JNK1/2 inhibitor SP 600125 on PSP-induced inhibition of MTT 
reduction and release of LDH. Differentiated H9c2 cells (7 days) were exposed to 25 µM 
PSP for 4 h (panels A and B) and 8 h  (panels C and D) in the presence and absence of 
SP 600125 as indicated. Following PSP exposure cell viability was assessed by measuring 
the metabolic reduction of MTT by mitochondrial dehydrogenases (B and D) and release 
of LDH (A and C). Data are expressed as the percentage of control cells (=100%) and 
represent the mean  SEM of at least three independent experiments each performed in 
quadruplicate (MTT) or sextuplicate (LDH). *p0.05, ** p<0.01, ***p<0.001 and 
****p<0.0001 versus control response. 
 
Figure 10. Effect of the JNK1/2 inhibitor SP 600125 on PSP-induced JNK1/2 activation. 
Differentiated H9c2 cells (7 day) were exposed to 25 µM PSP for A) 1 h, B) 2h, and C) 4 
h in the presence and absence of SP 600125 (10 µM; 30 min pre-incubation). Following 
PSP exposure JNK1/2 activation was assessed via Western blotting using a phospho-
specific JNK1/2 antibody. Samples were subsequently analysed on a separate blot using 
an antibody that recognises total JNK1/2. Data are expressed as the percentage of 
control cells (100%) and represent the mean  SEM of three independent experiments. 
*p0.05 versus untreated control cells.   
 
Figure 11. Effect of the JNK1/2 inhibitor SP 600125 on PSP-induced caspase 3 activation. 
Differentiated H9c2 cells (7 day) were exposed to 25 µM PSP for A) 1 h, B) 2h, and C) 4 
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h in the presence and absence of SP 600125 (10 µM; 30 min pre-incubation). Following 
PSP exposure caspase 3 activation was assessed via immunocytochemistry using active 
caspase 3 antibody (green) and DAPI counterstain for nuclei visualisation (blue). Scale 
bar = 100 µm. Images presented are from one experiment and representative of four. 
Quantified data are expressed as the percentage of control cells and represent the mean 
 SEM of four independent experiments. ** p<0.01, ***p<0.001 and ****p<0.0001, a) 
versus control and b) versus PSP alone treated cells. 
 
Figure 12. Effect of dansylated PSP on the viability of differentiated H9c2 cells monitored 
by MTT reduction and LDH release.  Differentiated H9c2 cells (7 day) were exposed to 
the indicated concentrations of dansylated PSP for 8 h. Following PSP exposure cell 
viability was assessed by measuring the metabolic reduction of MTT by mitochondrial 
dehydrogenases (A) and the release of LDH (B). Data are expressed as the percentage 
of control cells (=100%) and represent the mean  SEM of three (MTT) or four (LDH) 
independent experiments each performed in quadruplicate (MTT) or sextuplicate (LDH). 
*p0.05, ** p<0.01, ***p<0.001 and ****p<0.0001 versus control response. 
 
 
Figure 13. Visualisation of proteins labelled with dansylated PSP.  Differentiated H9c2 
cells were untreated or treated with dansylated PSP (8 h, 25 µM) and cell lysates 
processed and analysed by 2D gel electrophoresis using pH 3-10 gradient strips. Gels 
were visualised under UV light (panels A and B) prior to staining with ProtoBlue™safe 
colloidal Coomassie G-250 stain (panels C and D). Gel images were analysed using 
Progenesis SameSpots software and circled spots represent those labelled with 
dansylated PSP. Spot 1: nucleolar protein 58; Spot 2: tropomyosin -4; Spot 3: heat 
shock protein β-1. A list of identified proteins labelled by dansylated PSP is provided in 
Table 1.  
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Figure 14. Labelling of purified human heart tropomyosin with dansylated PSP. Human 
heart tropomyosin (10 µg) was incubated for 1 h in presence or absence of 
dansylated/unlabelled PSP (25 µM). Tropomyosin samples were then subjected to 10% 
(w/v) polyacrylamide gel electrophoresis and subsequently stained with coomassie blue 
(A) and visualised under UV light (B). Lane 1: tropomyosin incubated with Tris-buffered 
saline; Lane 2: tropomyosin incubated with DMSO; Lane 3: tropomyosin incubated with 
PSP; Lane 4: tropomyosin incubated with dansylated PSP. 
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Table 1. Identification of PSP-binding proteins in differentiated H9c2 cells. H9c2 cells 
treated with dansylated PSP (1 h, 25 µM) were analysed by 2D gel electrophoresis and 
PSP-labelled proteins identified using MALDI-TOF MSa (PMF) or MS/MSb as described in 
Materials and Methods. Sequence data was analysed using MASCOT software and 
reported according to percentage sequence coverage (SC%) or mascot score (ion scores 
for MS/MS  > 27 indicate identity or extensive homology; >51 for PMF). All identified 
proteins exhibited MASCOT scores which were considered statistically significant 
(p<0.05). 
 
 
Spot  
number 
Protein Accession 
no. 
PMF  
Sequence 
Coverage 
(%)a 
Identified 
Peptide 
sequence 
(MS/MS) 
Mascot 
scoreb 
 
kDa pI 
 
2 
 
3 
 
 
 
1 
 
Tropomyosin -4  
 
Heat shock 
protein β-1   
(HSP-27) 
 
Nucleolar protein 
58  
 
P09495 
 
P42930 
 
 
 
Q9Q286 
 
39 
 
 
 
 
 
32 
 
 
 
LFDQAFGVPR 
 
52/51 
 
80/27 
 
 
 
52/51 
 
28.5 
 
22.9 
 
 
 
59.5 
 
4.4 
 
6.1 
 
 
 
9.2 
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Figure 1 
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Figure 3. 
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Figure 4. 
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Figure 5.  
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Figure 6. 
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Figure 8. 
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L
D
H
 r
e
le
a
s
e
(%
 o
f 
c
o
n
tr
o
l 
re
s
p
o
n
s
e
)
C
o
n
tr
o
l
S
P
 6
0
0
1
2
5
P
S
P
S
P
 6
0
0
1
2
5
 +
 P
S
P
0
3 0
6 0
9 0
1 2 0
1 5 0
A
* * *
M
T
T
 r
e
d
u
c
ti
o
n
 (
%
 o
f 
c
o
n
tr
o
l 
re
s
p
o
n
s
e
)
C
o
n
tr
o
l 
S
P
 6
0
0
1
2
5
P
S
P
S
P
 6
0
0
1
2
5
 +
 P
S
P
0
3 0
6 0
9 0
1 2 0
1 5 0
B
* * * * * *
L
D
H
 r
e
le
a
s
e
(%
 o
f 
c
o
n
tr
o
l 
re
s
p
o
n
s
e
)
C
o
n
tr
o
l 
S
P
 6
0
0
1
2
5
P
S
P
S
P
 6
0
0
1
2
5
 +
 P
S
P
0
5 0
1 0 0
1 5 0
2 0 0
C
* * * * * * *
M
T
T
 r
e
d
u
c
ti
o
n
(%
 o
f 
c
o
n
tr
o
l 
re
s
p
o
n
s
e
)
C
o
n
tr
o
l 
S
P
 6
0
0
1
2
5
P
S
P
S
P
 6
0
0
1
2
5
 +
 P
S
P
0
3 0
6 0
9 0
1 2 0
1 5 0
D
* * *
 46 
 
 
Figure 10. 
 
  
 47 
 
Figure 11. 
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Figure 12. 
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Figure 13. 
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Supplementary data 
 
Figure 1 Effect of phenyl saligenin phosphate (PSP) on the viability of mitotic H9c2 cells 
monitored by MTT reduction and LDH release.  Mitotic H9c2 cells were exposed to the 
indicated concentrations of PSP for 4 h (panels A and B) 8 h (panels C and D). Following 
PSP exposure cell viability was assessed by measuring the metabolic reduction of MTT by 
cellular dehydrogenases (A and C) and release of LDH (B and D). Organophosphate 
concentration response curves were obtained by computer assisted curve fitting using 
Prism software  as described in Materials and Methods. Data are expressed as the 
percentage of control cells (=100%; ) and represent the mean  SEM of three 
independent experiments each performed in quadruplicate (MTT) or sextuplicate (LDH). 
*p0.05, ** p<0.01, ***p<0.001 and ****p<0.0001 versus control response. 
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Figure 2. Effect of phenyl saligenin phosphate (PSP) on the viability of differentiated 
H9c2 cells monitored by MTT reduction and LDH release.  Differentiated H9c2 cells (7 
day) were exposed to the indicated concentrations of PSP for 2 h (panel A), 4 h (panels 
B and D) 8 h (panels C and E). Following PSP exposure cell viability was assessed by 
measuring the metabolic reduction of MTT by cellular dehydrogenases (A, B, C) and 
release of LDH (D, E). Organophosphate concentration response curves were obtained by 
computer assisted curve fitting using Prism software  as described in Materials and Methods 
Data are expressed as the percentage of control cells (=100%; ) and represent the 
mean  SEM of at least three independent experiments each performed in quadruplicate 
(MTT) or sextuplicate (LDH). *p0.05, ** p<0.01, ***p<0.001 and ****p<0.0001 
versus control response. 
 
 
 
